top of page

Samsung Bioepis seeks EU approval for its biosimilar adalimumab candidate, SB5

The European Medicines Agency (EMA) is to reviewSamsung Bioepis’ Marketing Authorisation Application (MAA) for SB5.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page